Close
Saba Shaikh, MD Breast Oncology
Sherri Cervantez, MD Palliative Medicine, Thoracic Oncology
New discovery: Compounds that target enzyme MAP4K3
Daruka Mahadevan, MD, PhD, division chief, hematology-oncology, director of the Institute of Drug Development and associate director for clinical research at Mays Cancer Center at UT Health San Antonio and his team have identified a series of small molecule compounds that target an enzyme, MAP4K3, important to amino acid signaling in autophagy, impacting neurologic diseases and cancer.
Coming home: SA native, breast oncologist Jessica Treviño Jones, MD, returns home to fight cancer through education
Breast medical oncologist Jessica Treviño Jones, MD, returns to her San Antonio roots with a mission: to empower her community through cancer education and prevention. From humble beginnings to a leading role in cancer care, her journey inspires hope and change.
Head and neck cancer: signs, symptoms and treatment
Devi Meyyappan, MD, sits down to explain the signs, symptoms, and treatments of head and neck cancers.
Iron Overload Disorder (Hemochromatosis)
Chronic Lymphocytic Leukemia
Phase Ib Clinical Trial of Loncastuximab and Roflumilast Added to R-CHOP (Lo-RR-CHOP) for Treatment Naïve High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
This study is an investigator-initiated, phase I, single arm, open label clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome, defined as an NCCN-IPI score of 2 or higher.
